CPRX - Catalyst Pharmaceuticals: All Time High
- 88% technical buy signals.
- 16 new highs and up 49.40% in the last month.
- 78.74% gain in the last year.
- Price targets as high as $15.00.
The Barchart Chart of the Day belongs to the BioPharma company Catalyst Pharmaceuticals (CPRX). I found the stock by using Barchart.com to find the "Barchart New Highs" page, and then I clicked on pull-down to select stocks with new all-time highs. I then viewed the stocks on the list with the Flipcharts feature.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Barchart Technical Indicators:
- 88% technical buy signals but increasing
- 56.03+ Weighted Alpha
- 78.74% gain in the last year
- TrendSpotter buy signal
- Above its 20-, 50-, and 100-day moving averages
- 16 new highs and up 49.40% in the last month
- Relative Strength Index 77.56%
- Technical support level at $9.64
- Recently traded at $9.92 with 50-day moving average of $7.36
Fundamental factors:
- Market Cap $881 million
- Revenue expected to grow 42.60% this year and another 15.40% next year
- Earnings estimated increase 81.10% this year and an additional 17.90% next year
For further details see:
Catalyst Pharmaceuticals: All Time High